Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 8/20 | 0.45 |
| ▸ | ACHE | P22303 | 8/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804690 | 0.90 | MAPT (0.59) | MTNR1AMTNR1BMAPTL3MBTL1BCHE | |
| SCHEMBL16804693 | 0.88 | MAPT (0.53) | MTNR1AMTNR1BMAPTL3MBTL1BCHE | |
| SCHEMBL16804696 | 0.87 | MAPT (0.58) | MAPTL3MBTL1BCHEACHEFAAH | |
| SCHEMBL936949 | 0.82 | L3MBTL1 (0.61) | MAPTL3MBTL1LTA4HFFAR1 | |
| SCHEMBL16804700 | 0.82 | HTT (0.58) | MAPTL3MBTL1SLC6A5 | |
| SCHEMBL16804703 | 0.79 | KCNH2 (0.46) | MTNR1AMTNR1BLTA4HFFAR1AKR1B1 | |
| SCHEMBL16572084 | 0.77 | L3MBTL1 (0.69) | MAPTL3MBTL1BCHEFFAR1 | |
| SCHEMBL16572083 | 0.77 | MAPT (0.60) | MAPTL3MBTL1BCHE | |
| SCHEMBL16572102 | 0.77 | MAPT (0.59) | MAPTL3MBTL1BCHE | |
| SCHEMBL16804687 | 0.77 | L3MBTL1 (0.67) | MAPTL3MBTL1BCHEFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957238-B2 | Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-9586911-B2 | Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9102633-B2 | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | MTNR1A 1553/4885MTNR1B 967/4885MAPT 4487/4885 |
| US-20170305868-A1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | MTNR1A 2086/4885MTNR1B 1014/4885MAPT 4148/4885 |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | MTNR1A 2086/4885MTNR1B 1014/4885MAPT 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.